Brainstorm Cell Therapeutics Inc.
BCLIBrainstorm Cell Therapeutics reduced operating and net losses in FY2025 through cost discipline, yet continues to incur significant negative cash flows from operations due to ongoing clinical development, with no near-term revenue prospects.
NASDAQ
Healthcare
Biotechnology
$0.82
-0.02(-2.4%)
52W $0.48 – $1.36
AI-generated
Brainstorm Cell Therapeutics reduced operating and net losses in FY2025 through cost discipline, yet continues to incur significant negative cash flows from operations due to ongoing clinical development, with no near-term revenue prospects.
$9MMkt Cap
$851.1KRev TTM
-$11MNI TTM
-0.9xP/E TTM
Latest Earnings
10-K
FY FY2025Mar 30, 2026Brainstorm Cell Therapeutics reduced operating and net losses in FY2025 through cost discipline, yet continues to incur significant negative cash flows from operations due to ongoing clinical development, with no near-term revenue prospects.
What Changed Recently
Fundamentals
How The Business Makes Money
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; and Phase II clinical trial for the treatment of progressive multiple sclerosis and alzheimer's disease, as well as for other neurodegenerative diseases. The company has a partnership with Catalent for manufacturing NurOwn. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.
Industry Biotechnology
Analyst View
Company Profile
CIK0001137883
ISINUS10501E3009
CUSIP10501E201
Phone201 488 0460
Address1325 Avenue of Americas, New York City, NY, 10019, US
SEC EDGAR